ArticleUrolithiasis2025
Subclinical papillary tip calcifications in stone-naïve kidneys: micro-ct quantification, osteopontin expression, and associations with urinary and clinical risk factors.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subepithelial papillary calcifications, encompassing both Randall's plaques (interstitial) and Randall's plugs(intraluminal), are established niduses for stone formation, yet their distribution and determinants in stone-naïve individuals remain poorly characterized. We hypothesized that subclinical papillary calcifications are present in non-stone-formers and associated with urinary and clinical risk factors similar to those in stone formers. In this retrospective cross-sectional study, we analyzed 50 patients undergoing nephrectomy for renal or upper urinary tract cancer (June 2019-January 2023). Patients with prior stone disease, calcium/vitamin supplementation, or metabolic disorders were excluded. High-resolution micro-computed tomography (micro-CT, 20 μm voxels) quantified mineral-to-parenchyma (M/P) ratios across papillary zones, and osteopontin (OPN) immunohistochemistry was performed on matched sections. Given the 20 μm spatial resolution limit of micro-CT, any papillary tip calcified lesion (PCL) ≥ 1 mm³ was considered clinically relevant; such lesions were present in 46% of kidneys. PCL + patients were older, more frequently hypertensive, and exhibited lower urine volume (median 1200 vs. 1600 mL, p < 0.001), lower urinary citrate (p = 0.002), higher urine specific gravity (p = 0.001), and elevated M/P ratios in the middle medullary zone (p = 0.003). OPN staining was increased in loops of Henle in PCL + cases and correlated with mineral burden. Multivariable analysis identified lower urine volume, higher urinary calcium, and hypertension as independent predictors of PCL (area under curve = 0.93). These findings indicate that PCLs are common in stone-naïve kidneys and are associated with specific urinary and systemic risk factors. Early interventions targeting urine chemistry and vascular health may influence mineral deposition and delay kidney stone development.
Indexed as
Identifiers
41428118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.